Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)
暂无分享,去创建一个
I. Kahramanoglu | A. Pletnev | N. Bizzarri | T. Zwimpfer | Marcus Vetter | Zoia Razumova | Joanna Kacperczyk-Bartnik | Charalampos Theofanakis | Esra Bilir | Khayal Gasimli | Andrej Cokan | Tanja Nikolova | Alexander B Shushkevich | A. Strojna | Tereza Cicakova | Céline Montavon | Gilberto Morgan | V. Heinzelmann-Schwarz
[1] D. Cibula,et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. , 2024, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] V. Heinzelmann-Schwarz,et al. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers , 2023, Cancer medicine.
[3] J. Ledermann,et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2023, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Libra,et al. SnapShot: Cancer chemotherapy , 2023, Cell.
[5] A. Oaknin,et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Xueyun Gao,et al. Platinum-based drugs for cancer therapy and anti-tumor strategies , 2022, Theranostics.
[7] M. Castells,et al. Hypersensitivity Reactions to Platinum Agents and Taxanes , 2021, Clinical Reviews in Allergy & Immunology.
[8] P. Scollo,et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review) , 2021, International journal of oncology.
[9] P. Bonadonna,et al. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper , 2021, Allergy.
[10] A. Yasmeen,et al. Multiple lines of chemotherapy for patients with high‐grade ovarian cancer: Predictors for response and effect on survival , 2020, International journal of cancer.
[11] Jenifer R Prosperi,et al. Mechanisms of Taxane Resistance , 2020, Cancers.
[12] R. Berardi,et al. Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management , 2020, Cancer management and research.
[13] D. Tiezzi,et al. Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort , 2020, Journal of surgical oncology.
[14] R. Edmondson,et al. Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases , 2019, Oncology Research and Treatment.
[15] D. Cohn,et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. , 2019, Gynecologic oncology.
[16] F. Landoni,et al. Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Gloria S. Huang,et al. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer , 2018, Journal of Cancer Research and Clinical Oncology.
[18] A. Neugut,et al. Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. , 2017, Obstetrics and gynecology.
[19] A. Cervantes,et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] D. Cohn,et al. Outpatient desensitization in selected patients with platinum hypersensitivity reactions. , 2017, Gynecologic oncology.
[21] I. Christensen,et al. Classification of Ovarian Cancer Surgery Facilitates Treatment Decisions in a Gynecological Multidisciplinary Team , 2017, International Journal of Gynecologic Cancer.
[22] W. Barry,et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. , 2016, The journal of allergy and clinical immunology. In practice.
[23] P. Tchounwou,et al. Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.
[24] J. Boulanger,et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. , 2014, Current oncology.
[25] E. Kohn,et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions , 2013, British Journal of Cancer.
[26] P. Demoly,et al. Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of the Drug Allergy Interest Group , 2013, Allergy.
[27] M. Castells,et al. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization , 2012, Cancer Immunology, Immunotherapy.
[28] P. Demoly,et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement , 2010, Allergy.
[29] M. Pagani. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. , 2010, The Medical clinics of North America.
[30] J. Coebergh,et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. , 2009, Gynecologic oncology.
[31] Y. Miyagi,et al. Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic Malignancies , 2009, International Journal of Gynecologic Cancer.
[32] Y. Itoh,et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy , 2005, Cancer Chemotherapy and Pharmacology.
[33] G. Shepherd. Hypersensitivity reactions to chemotherapeutic drugs , 2003, Clinical reviews in allergy & immunology.
[34] P. Sabbatini,et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. , 2002, Gynecologic oncology.
[35] C. Genestie,et al. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy. , 2017, European journal of gynaecological oncology.
[36] A. Costello,et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. , 2016, Cancer treatment reviews.